SEC Stock Data Quick Answer Xeris Biopharma Holdings, Inc. reported Diluted EPS of $0.00 per share for fiscal year 2025. Xeris Biopharma Holdings, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $0.00 +100.0% 2024 -$0.37 +17.8% 2023 -$0.45 +35.7% 2022 -$0.70 +54.8% 2021 -$1.55 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Net Income of $554.0 thousand for fiscal year 2025. Xeris Biopharma Holdings, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 $554.0K +101.0% 2024 -$54.84M +11.9% 2023 -$62.26M +34.2% 2022 -$94.66M +22.9% 2021 -$122.72M -34.7% 2020 -$91.14M — Quarterly Net Income Quarter Ending Net … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Revenue (ASC 606) of $291.85 million for fiscal year 2025. Xeris Biopharma Holdings, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $291.85M +43.7% 2024 $203.07M +23.9% 2023 $163.91M +48.7% 2022 $110.25M +122.3% 2021 $49.59M +146.0% 2020 $20.16M — Quarterly Revenue (ASC … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Total Revenue of $291.85 million for fiscal year 2025. Xeris Biopharma Holdings, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $291.85M +43.7% 2024 $203.07M +23.9% 2023 $163.91M +48.7% 2022 $110.25M +122.3% 2021 $49.59M +142.7% 2020 $20.43M — Quarterly Total Revenue Quarter Ending Total … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Total Revenue of $291.85 million for fiscal year 2025. Xeris Biopharma Holdings, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $291.85M+43.7% $203.07M+23.9% $163.91M+48.7% $110.25M+122.3% $49.59M+142.7% $20.43M Revenue (ASC 606) $291.85M+43.7% $203.07M+23.9% $163.91M+48.7% $110.25M+122.3% $49.59M+146.0% $20.16M Net Income $554.0K+101.0% -$54.84M+11.9% -$62.26M+34.2% -$94.66M+22.9% … Read more
Quick Answer XERIANT, INC. reported Shares Outstanding of 695.75 million shares for fiscal year 2025. XERIANT, INC. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 695.75M +32.6% 2024 524.85M +34.8% 2023 389.43M +6.6% 2022 365.24M +24.7% 2021 292.82M +320.8% 2020 69.58M — 2019 0 -100.0% 2018 69.58M +0.0% 2017 69.58M +18.3% … Read more
Quick Answer XERIANT, INC. reported Gross Profit of $57.5 thousand for fiscal year 2018. XERIANT, INC. Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2018 $57.5K -86.8% 2017 $436.6K -42.1% 2016 $753.6K -21.5% 2015 $960.0K +6.7% 2014 $899.9K +20.5% 2013 $747.1K — Quarterly Gross Profit Quarter Ending Gross Profit YoY QoQ March … Read more
Quick Answer XERIANT, INC. reported Operating Income of -$1.37 million for fiscal year 2025. XERIANT, INC. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$1.37M +28.4% 2024 -$1.91M +7.1% 2023 -$2.05M +81.4% 2022 -$11.01M -400.7% 2021 -$2.20M -506.3% 2020 -$362.7K -329.9% 2019 -$84.4K +73.9% 2018 -$322.8K +51.3% 2017 -$662.8K +16.6% 2016 … Read more
Quick Answer XERIANT, INC. reported R&D Expense of $69.3 thousand for fiscal year 2025. XERIANT, INC. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $69.3K -64.7% 2024 $196.4K — 2023 $0.00 -100.0% 2022 $5.27M +1311.8% 2021 $373.1K +5751.8% 2020 $6.4K -24.0% 2019 $8.4K — Quarterly R&D Expense Quarter Ending R&D Expense … Read more
Quick Answer XERIANT, INC. reported Stockholders Equity of -$5.82 million for fiscal year 2025. XERIANT, INC. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 -$5.82M -1.2% 2024 -$5.75M -51.7% 2023 -$3.79M -2211.4% 2022 -$164.1K -117.8% 2021 $922.0K +3052.8% 2020 -$31.2K +7.8% 2019 -$33.8K — 2018 $0.00 +100.0% 2018 -$4.07M -25.9% 2017 … Read more